<?xml version='1.0' encoding='utf-8'?>
<document id="23129213"><sentence text="Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes."><entity charOffset="14-24" id="DDI-PubMed.23129213.s1.e0" text="crizotinib" /></sentence><sentence text="Crizotinib (Xalkori) is an orally available potent inhibitor of multiple tyrosine kinases, including anaplastic lymphoma kinase and mesenchymal-epithelial transition factor"><entity charOffset="0-10" id="DDI-PubMed.23129213.s2.e0" text="Crizotinib" /><entity charOffset="73-81" id="DDI-PubMed.23129213.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.23129213.s2.e0" e2="DDI-PubMed.23129213.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23129213.s2.e0" e2="DDI-PubMed.23129213.s2.e1" /></sentence><sentence text=" Objectives of the present study were as follows: 1) to characterize crizotinib time-dependent inhibition (TDI) potency for CYP3A in human liver microsomes (HLM) and cryopreserved human hepatocytes suspended in human plasma (HSP); 2) to characterize crizotinib enzyme induction potency on CYP3A4 in cryopreserved human hepatocytes; 3) to predict crizotinib steady-state plasma concentrations in patients (e"><entity charOffset="69-79" id="DDI-PubMed.23129213.s3.e0" text="crizotinib" /><entity charOffset="250-260" id="DDI-PubMed.23129213.s3.e1" text="crizotinib" /><pair ddi="false" e1="DDI-PubMed.23129213.s3.e0" e2="DDI-PubMed.23129213.s3.e0" /><pair ddi="false" e1="DDI-PubMed.23129213.s3.e0" e2="DDI-PubMed.23129213.s3.e1" /></sentence><sentence text="g" /><sentence text=", autoinhibition and autoinduction) using the mechanistic dynamic model, Simcyp population-based simulator; and 4) to predict a clinical crizotinib-midazolam interaction using the dynamic model as well as the static mathematical model" /><sentence text=" Crizotinib inactivation constant (K(I)) and maximum inactivation rate constant (k(inact)) for TDI were estimated as, respectively, 0"><entity charOffset="1-11" id="DDI-PubMed.23129213.s6.e0" text="Crizotinib" /></sentence><sentence text="37 µM and 6" /><sentence text="9 h(-1) in HLM and 0" /><sentence text="89 µM and 0" /><sentence text="78 h(-1) in HSP" /><sentence text=" Thus, crizotinib inactivation efficiency (k(inact)/K(I)) was ∼20-fold lower in HSP relative to HLM"><entity charOffset="7-17" id="DDI-PubMed.23129213.s11.e0" text="crizotinib" /></sentence><sentence text=" Crizotinib E(max) and EC(50) for CYP3A4 induction (measured as mRNA expression) were estimated as 6"><entity charOffset="23-29" id="DDI-PubMed.23129213.s12.e0" text="EC(50)" /></sentence><sentence text="4- to 29-fold and 0" /><sentence text="47 to 3" /><sentence text="1 µM, respectively" /><sentence text=" Based on these in vitro parameters, the predicted crizotinib steady-state area under plasma concentration-time curve (AUC) with HLM-TDI was 2"><entity charOffset="51-61" id="DDI-PubMed.23129213.s16.e0" text="crizotinib" /></sentence><sentence text="1-fold higher than the observed AUC, whereas that with HSP-TDI was consistent with the observed result (≤1" /><sentence text="1-fold)" /><sentence text=" The increase in midazolam AUC with coadministration of crizotinib (21-fold) was significantly overpredicted using HLM-TDI, whereas the prediction using HSP-TDI (3"><entity charOffset="56-66" id="DDI-PubMed.23129213.s19.e0" text="crizotinib" /></sentence><sentence text="6-fold) was consistent with the observed result (3" /><sentence text="7-fold)" /><sentence text=" Collectively, the present study demonstrated the value of HSP to predict in vivo CYP3A-mediated drug-drug interaction" /><sentence text="" /></document>